DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more



Bioavailability Study of Leflunomide Tablets Under Fed Conditions

Information source: Par Pharmaceutical, Inc.
Information obtained from ClinicalTrials.gov on June 20, 2008
Link to the current ClinicalTrials.gov record.

Condition(s) targeted: To Determine Bioequivalence Under Fed Conditions.

Intervention: Leflunomide (Drug); ARAVA (Drug)

Phase: Phase 1

Status: Completed

Sponsored by: Par Pharmaceutical, Inc.

Official(s) and/or principal investigator(s):
Xueyu Chen, Principal Investigator, Affiliation: Pharma Medica Research Inc.

Summary

To compare the single-dose Bioavailability of Kali and Aventis

Clinical Details

Official title: To Compare the Relative Bioavailability of Leflunomide 20mg Tablets (Kali) With That of ARAVA 20mg Tablets(Aventis) Under Fed Conditions

Study design: Other, Randomized, Open Label, Crossover Assignment

Primary outcome: Rate and Extend of Absorption

Detailed description: To compare the relative Bioavailability of leflunomide 20mg tablets with that of ARAVA 20mg tablets in healthy female subjects under fed conditions

Eligibility

Minimum age: 18 Years. Maximum age: 65 Years. Gender(s): Female.

Criteria:

Inclusion Criteria:

- Subjects will meet all of the following criteria within 30 days prior to first drug

administration(except inclusion #8)

- Healthy, surgically sterile (hysterectomy, bilateral oophorectomy) or postmenopausal

(for al least 1 year)female subjects, 18 to 65 years of age(inclusive)

- Indicate non-child bearing status by one of the following criteria:

Indication of successful hysterectomy. No spontaneous menses for al least 1 year, must have luteinizing hormone (LH) and follicle stimulating hormone(FSH) levels within postmenopausal range.

Indication of successful bilateral oophorectomy.

- Body weight within 20% of the appropriate weight for the subject's height and frame

(as published in the 1983 Metropolitan Life Insurance Company Scale, Statistical Bureau)

- Negative for:

HIV Hepatitis B surface antigen and Hepatitis C antibody Urine tests for drugs of abuse (marijuana, amphetamines, barbiturates, cocaine, opiates, benzodiazepines and methadone).

Serum HCG consistent with pregnancy.

- No significant disease or clinically significant findings in a physical examination.

- No clinically significant findings in vital signs measurements and a 12-lead

electrocardiogram(ECG)

- Subjects who have received leflunomide within 4 months must have an

A77-1726(Metabolite) level below 0. 01ug/ml and no subsequent administration of leflunomide since that test. Note: The 30 day screening limit does not apply to this inclusion criterion.

- Be informed of the nature of the study and given written consent prior to receiving

any study procedures.

Exclusion Criteria:

- Subject fulfilling any of the following criteria will be excluded from the study.

- Known history or presence of any clinically significant medical condition.

- Known or suspected carcinoma.

- Known history or presence of:

- Hypersensitivity or idiosyncratic reaction to leflunomide and/or any other drug

substances with similar activity.

- Alcoholism within the last 12 months.

- Drug dependence and/ or substance abuse.

- On a special diet within 4 weeks prior to drug administration(e. g. liquid, protein,

raw food diet).

- Participated in another clinical trail or received an investigational product 30 days

prior to drug administration.

- Donated up to 250 ml of blood in the past 45 days OR donated from 250 ml to 500 ml in

the past 45 days OR donated 501 ml or more of blood in the past 56 days (based on the Canadian Blood Services guideline for blood donation).

- Requirement of any medication (prescription and/ or over-the-counter) on a routine

basis, with the exception of hormonal replacement therapy, nutritional supplements and/or occasional use of common analgesics.

- Difficulty fasting or consuming the standard meals.

Locations and Contacts

Additional Information

Starting date: December 2003
Ending date: January 2004
Last updated: April 3, 2008

Page last updated: June 20, 2008

-- advertisement -- The American Red Cross
 
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2012